TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Light Therapy in the Treatment of Leg Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active duty soldier~* Exertional leg pain of greater than 3 months duration~* Documented bone scintigraphic evidence for tibial stress reaction or fracture~Exclusion Criteria:~* Known leg Pathology other than stress reaction or fracture~* Service members known to be leaving area within next 6 months~* Pregnant females~* High risk cardiopulmonary patients~* Patients with assisted walking devices~* Patients with two or more cardiac risk factors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Infrared Light Therapy (Type: EXPERIMENTAL): Intervention: The use of infrared light therapy for the treatment of tibial fracture. The treatment was assigned three times a week for four weeks.
- Standard of Care (Type: PLACEBO_COMPARATOR): Standard of care was characterized by the use of standard medical treatment to include medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Location of Lower Extremity Deep Vein Thrombosis by Emergency Physicians Using Portable Compression Ultrasonography

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given informed consent and signed consent~* The patient must be a member or beneficiary of a health insurance plan~* Patient consulting in the vascular exploration and medicine department for suspected first episode of deep vein thrombosis~* Ambulatory patient: defined as any outpatient coming in for a consult directly from their place of residence or via the emergency department~* Patient does not have a history of venous thromboembolism~Exclusion Criteria:~* The patient is participating in another study~* The patient is in an exclusion period determined by a previous study~* The patient is an adult under any kind of guardianship~* The patient refuses to sign the consent~* It is not possible to correctly inform the patient~* Patient has a history of venous thromboembolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Suspected first episode of DVT (Type: OTHER): The study population consists of patients presenting with suspected first episode of DVT at the Nîmes University Hospital.~Intervention: portable venous compression ultrasonography Intervention: venous compress ultrasonography Intervention: Doppler ultrasound of the lower limbs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Plan to Obtain Clinical Experience and Follow up Data on the Use of the ProxiFuse Hammer Toe Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Greater than 18 years of age~* Has a hammertoe deformity causing daily pain and is a surgical candidate for hammertoe procedure in the 2nd, 3rd and/or 4th toe that has failed non-operative measures~* Capable of completing self-administered questionnaires~* Be willing and able to return for all study-related follow up procedures~* Has not participated in any other research protocol within the last 30 days and will not participate in any other research protocol during this study~* If female, is either using contraception or is postmenopausal, or male partner is using contraception~* Has been informed of the nature of the study, agreeing to its requirements, and have signed the informed consent approved by the IRB~Exclusion Criteria:~* Active bacterial infection of the foot/feet to be treated~* Previous hammertoe correction that requires a revision to a toe to be treated under this study~* Patient is on chronic anticoagulation due to a bleeding disorder or has taken anticoagulants within 10 days prior to surgery~* Muscular imbalance, peripheral vascular disease that prohibits adequate healing, or a poor soft tissue envelope in the surgical field, absence of musculoligamentous supporting structures, or peripheral neuropathy~* Patient is not ambulatory or requires an additional surgical procedure that would prohibit the patient from following standard ProxiFuse post-operative recovery procedures~* Additional foot and ankle surgical procedures required during the index procedure other than foot procedures, lapidus and gastrocnemius recession~* Suspected or known allergic reaction to Nickel or Titanium metals~* Co-morbidity that reduces life expectancy to less than 12 months; or~* Patient is a prisoner or ward of the state

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of Eptifibatide in Patients With Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18 and 55 years~2. Have confirmed diagnosis of sickle cell anemia or sickle beta zero thalassemia~3. Have a serum creatinine \</= 1.2 mg/dl~4. Have serum transaminase values \< 3 times upper limits of normal~5. Have a platelet count \>/= 150 x 10\^9/L~6. Have normal baseline coagulation profile~7. Sudden onset of pain involving one or more sites and typical of usual pain episodes~8. Have adequate intravenous access~9. Be able to understand the requirements of the study and be willing to give informed consent~10. Women of child-bearing age must be practicing (and will continue to practice for the course of the study) an adequate method of contraception (oral contraception, depo-provera, bilateral tubal ligation or barrier method)~Exclusion Criteria:~1. Have a baseline hemoglobin \< 6.0 gm/dl~2. Have a history of major gastrointestinal bleeding or a bleeding diathesis~3. Have an ongoing episode of acute chest syndrome~4. Have a past history of clinically overt stroke(s)~5. Have severe hypertension (systolic blood pressure \> 200mmHg and/or diastolic BP \>110mmHg) not adequately controlled on hypertensive medication~6. Have had major surgery within the six weeks preceding enrollment~7. Are pregnant or breastfeeding~8. Are on chronic anticoagulation or antiplatelet (including non-steroidal anti-inflammatory drugs) therapy~9. Have a history of metastatic cancer~10. Are on a chronic transfusion program or have received a blood transfusion in the prior 8 weeks~11. Have a positive urine toxicology screen for phencyclidine, cocaine or amphetamines.~12. Have a history of alcohol abuse~13. Have received any investigational drugs within the past 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the eptifibatide arm will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
- 2 (Type: PLACEBO_COMPARATOR): As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Renal allograft recipients who received a steroid-sparing immunosuppression protocol with rabbit anti-thymocyte globulin (Thymoglobulin) induction~* Patient must have previously enrolled in protocol entitled The use of urinary PCR test to help detect rejection in kidney transplant patients~* Recipients must agree to undergo all standard post-transplant protocol biopsies~* Recipients must be at least 3 months post-transplant and the three most recent urinary profiles must demonstrate immunologic quiescence as determined by measurement of Granzyme B and Perforin copy numbers~* Patient must provide informed consent to participate in the research study~Exclusion Criteria:~* Patient is a high-risk recipient (defined as peak or current PRA \>50% or a re-transplant recipient who lost prior graft within 1 year due to immunologic reasons)~* Patients who require maintenance steroids for another medical condition (such as asthma)~* Patients who are taking less than 1 gram/day of mycophenolate mofetil~* Multiple organ transplant recipients (such as kidney-pancreas)~* Patients with one or more acute rejection episodes within the first 3 months after transplant~* Three-month protocol biopsy showing clinical acute rejection (BANFF grade 1a or higher)~* Patient with documented or suspected non-compliance with transplant medications in the first 3 months after transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (6 to 8 ng/mL) (Type: ACTIVE_COMPARATOR): Target tacrolimus trough concentration of 6 to 8 ng/mL
- Arm 2 (3 to 5 ng.mL) (Type: ACTIVE_COMPARATOR): Target tacrolimus trough concentration of 3 to 5 ng/mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Completed study LA38-0411~2. Females of childbearing potential must have a negative pregnancy test result at Visit 1. In addition, if applicable, they must:~   * Use an effective method of contraception according to local requirements, during the study and within 30 days following their last dose of study medication, OR~  * Have had a tubal ligation (supporting evidence required), OR~  * Have had a hysterectomy (supporting evidence required), OR~  * Participate in a non-heterosexual lifestyle, OR~  * Have a male sexual partner who has been sterilized (supporting evidence required)~3. Fertile heterosexual males and/or their partners must agree to use an effective method of contraception during the study and for 30 days following the last dose of study medication~4. All patients and/or their authorized legal representatives must provide signed and dated written informed consent prior to the first study intervention, and assent will be obtained from patients who are considered to be minors. Patients must be able to adhere to study restrictions, appointments, and evaluation schedules.~Exclusion Criteria:~1. Plan to participate in another clinical trial at any time from the day of enrollment until 30 days post-treatment in the current study~2. For only those patients who were treated with deferoxamine in study LA38-0411 (Group 2): Presence of any medical condition (including clinically significant laboratory abnormalities, such as ALT (alanine aminotransferase) ≥ 5 x ULN or creatinine ≥ 2 x ULN), psychological condition, or psychiatric condition which in the opinion of the investigator would cause participation in the study to be unwise.~3. Pregnant, breastfeeding, or planning to become pregnant during the study period.~4. Treatment failure after 1 year on deferiprone which in the investigator's judgment indicates the need for the patient to be started on a different iron chelator

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Deferiprone 3 years (Type: EXPERIMENTAL): Patients in this group are those who were randomized to the deferiprone arm in study LA38-0411, and hence will receive deferiprone for a total of 3 years (1 year in the initial study plus 2 years in the extension study).
- Group 2: Deferiprone 2 years (Type: EXPERIMENTAL): Patients in this group are those who were randomized to the deferoxamine arm in study LA38-0411, and hence will receive deferiprone for 2 years (both of them in the extension study).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Impact of a Mental Health Support Program on of Medical Residents' Stigmatization Towards People With Lived Experience

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Family Medicine residency program students in the1st year of their program.~* Provision of informed consent In good standing in their program.~Exclusion Criteria:~• Medical Students who are not enrolled in Dalhousie University Family Medicine residency program

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adult mental health support program (Type: None): The investigators will evaluate the Impact of an Adult mental health support program on stigmatization and confidence of medical residents working with people with mental health concerns. The intervention will be delivered to approximately 30 residents from the University of Dalhousie family medicine residency program from the 2021-2022 academic year. The training will be delivered by resident groups. The first group will receive the PSP training October - November 2022. The second will receive the training November 2021 to February 2022. The third will take the training March to May 2022. Each group will include approximately 10 residents.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Histologic diagnosis of melanoma.~2. Unresectable Stage III or IV disease~3. Documented progressive disease based on radiographic, clinical or pathologic assessment.~4. No more than three prior anticancer regimens (BRAF/MEK inhibitors, IL-2 or investigational agents) including no more than one chemotherapy-containing regimen for advanced (recurrent, locally advanced or metastic) disease.~5. Measurable disease.~6. Life expectancy ≥ 12 weeks.~7. If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 70 days following last treatment.~8. Availability of tumor tissue for central laboratory analyses.~Key Exclusion Criteria:~1. Previous treatment with anti-CD27 antibody, ipilimumab or other anti-CTLA-4 targeted therapies. Previous therapy with other checkpoint blockers such as anti-PD-1 or anti-PD-L1 is acceptable, unless treatment was discontinued for intolerance.~2. For patients enrolled to Phase II Cohort B: Previous administration of vaccine therapy targeting NY-ESO-1.~3. BRAF/MEK inhibitors within 2 weeks prior to first dose of study treatment.~4. Chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to first dose of study treatment.~5. Monoclonal based therapies within 4 weeks and all other immunotherapy within 2 weeks prior to first dose of study treatment.~6. Systemic radiation therapy within 4 weeks, focal radiotherapy within 2 weeks and radiopharmaceuticals (strontium, samarium) within 8 weeks prior to first dose of study treatment.~7. Ocular Melanoma~8. Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancers; or any other cancer from which the patient has been disease-free for at least 3 years.~9. Active, untreated central nervous system metastases.~10. Active autoimmune disease or documented history of autoimmune disease.~11. Active diverticulitis~12. Significant cardiovascular disease including CHF or poorly controlled hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase l: varlilumab and ipilimumab (Type: EXPERIMENTAL): None
- Phase ll: varlilumab & ipilimumab, +/- CDX-1401 & poly-ICLC. (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Femoral vs Saphenous Nerve Blocks on Function After ACL Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-65~2. Upcoming ACL reconstruction using patellar tendon autograft scheduled at Hershey Medical Center or the Hershey Outpatient Surgical Center (HOSC)~Exclusion Criteria:~1. Documented neuropathy~2. Skeletally immature~3. Previous knee surgery~4. Inability to provide informed consent~5. ACL reconstruction with other tendon repairs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- proximal nerve block (Type: ACTIVE_COMPARATOR): The anesthesiologist will administer a proximal nerve block if specified in the randomization envelope.
- distal nerve block (Type: ACTIVE_COMPARATOR): The anesthesiologist will administer a distal nerve block if specified in the randomization envelope.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: His Bundle Recording From Subclavian Vein

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Age ≥ 18 years Male or Female Patients undergoing HIS bundle recording from the subclavian vein using a stylet driven pacemaker lead and commercially available sheath~Exclusion Criteria:~Patients who are unwilling or unable to sign the informed consent Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 105 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per RECIST v1.1~* Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting if such a therapy exists~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Ability to swallow tablets~* Adequate bone marrow and organ function, as defined by the protocol~Exclusion Criteria:~* Participants with known or suspected CNS metastases, untreated CNS metastases, or with the CNS as the only site of disease (patients with controlled brain metastasis allowed to enroll)~* Ocular melanoma~* Any significant acute or chronic medical illness~* Prior malignancy~* Other active malignancy requiring concurrent intervention~* Prior organ allograft or allogeneic bone marrow transplantation~* Participants with active, known, or suspected autoimmune disease~* Requirement for daily supplemental oxygen~* Uncontrolled or significant cardiovascular disease~* Pre-existing liver disease~* Gastrointestinal disease known to interfere with absorption~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation (Type: EXPERIMENTAL): BMS-986242 administered in combination with Nivolumab
- Dose Expansion (Type: EXPERIMENTAL): BMS-986242 administered in combination with Nivolumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy